Get started
Author

Octavio Costa Filho

Observed name: Costa Filho, Octavio
OpenAlex ID: A5113060007
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
2025 · Sundar Jagannath, Thomas G. Martin, et al. · Journal of Clinical Oncology · 138
CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma
2023 · Simon J. Harrison, Tamia Nguyen, et al. · Blood · 99
LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma – 2-year follow-up (final analysis)
2024 · María-Victoria Mateos, Katja Weisel, et al. · Leukemia · 37
PDF
The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)
2023 · Jens Hillengass, Adam D. Cohen, et al. · Blood · 29
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial
2025 · Roberto Mina, Anne K Mylin, et al. · The Lancet Haematology · 23
PDF
Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial
2024 · Rakesh Popat, Albert Oriol, et al. · Blood · 14
Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis.
2024 · Luciano J. Costa, Katja C Weisel, et al. · Journal of Clinical Oncology · 14
The Phase 2 Cartitude-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1–3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)
2024 · Jens Hillengass, Adam D. Cohen, et al. · Transplantation and Cellular Therapy · 6
P-005 Effectiveness of Bridging Therapy Corresponds to Improved Outcomes After Receiving CAR-T Therapy: Phase 3 CARTITUDE-4 Study of Patients With Relapsed, Lenalidomide-Refractory Multiple Myeloma
2024 · Sébastien Anguille, Xavier Leleu, et al. · Clinical Lymphoma Myeloma & Leukemia · 5
Ciltacabtagene Autoleucel vs Standard of Care in Patients With Functional High-Risk Multiple Myeloma: CARTITUDE-4 Subgroup Analysis
2024 · Luciano Costa, Katja Weisel, et al. · Clinical Lymphoma Myeloma & Leukemia · 4
Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 CARTITUDE-4 Trial
2023 · M Hasib Sidiqi, Paolo Corradini, et al. · Blood · 4
Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Lines of Therapy
2023 · Roberto Mina, Anne K Mylin, et al. · Blood · 4
MM-522 Effectiveness of Bridging Therapy Corresponds to Improved Outcomes After Receiving CAR-T Therapy: Phase 3 CARTITUDE-4 Study of Patients With Relapsed, Lenalidomide-Refractory Multiple Myeloma
2024 · Yi Lin, Xavier Leleu, et al. · Clinical Lymphoma Myeloma & Leukemia · 3
P904: Locommotion: a Prospective, Observational, Multinational Study of Real-life Current Standards of Care in Patients With Relapsed/refractory Multiple Myeloma– Final Analysis at 2-year Follow-up
2023 · Philippe Moreau, Katja Weisel, et al. · HemaSphere · 3
Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial
2025 · Rakesh Popat, Albert Oriol, et al. · Transplantation and Cellular Therapy · 2
Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial
2024 · Noffar Bar, Roberto Mina, et al. · Blood · 2
PDF
P-324 LocoMMotion: a prospective, observational, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma–final analysis at 2-year follow-up
2023 · Katja Weisel, Philippe Moreau, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
P-057 Comparative Efficacy of Cilta-Cel vs Approved Comparator Treatments for Patients With Relapsed/Refractory Multiple Myeloma With 1–3 Prior Lines of Therapy: A Network Meta-Analysis
2024 · Roberto Mina, Abdullah Khan, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Effectiveness of Bridging Therapy Corresponds to Improved Outcomes After Receiving CAR-T Therapy: Phase 3 CARTITUDE-4 Study of Patients With Relapsed, Lenalidomide-Refractory Multiple Myeloma
2024 · Yi Lin, Xavier Leleu, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Subgroup Analysis by Cytogenetic Risk
2024 · Roberto Mina, Binod Dhakal, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
MM-567 Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Subgroup Analysis by Cytogenetic Risk
2024 · Roberto Mina, Binod Dhakal, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
MM-549 Ciltacabtagene Autoleucel vs Standard of Care in Patients With Functional High-Risk Multiple Myeloma: CARTITUDE-4 Subgroup Analysis
2024 · Luciano Costa, Katja Weisel, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma: CARTITUDE-2 cohort A expansion subgroup.
2024 · Adam D. Cohen, Peter M. Voorhees, et al. · Journal of Clinical Oncology · 1
Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma and 1–3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 Cartitude-4 Trial
2024 · M Hasib Sidiqi, Paolo Corradini, et al. · Transplantation and Cellular Therapy · 1
MM-464 LocoMMotion: A Prospective, Observational, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma – Final Analysis at 2-Year Follow-up
2023 · Philippe Moreau, Katja Weisel, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
PDF
Works count: 37
Citation count: 397
H-index: 7
I10-index: 7
Year
Topic
Type